News📰: Gilead to Buy Arcus Stake

Gilead Sciences Inc. considers acquiring a stake in Arcus Biosciences Inc., a cancer therapeutics company, that is backed by Alphabet (Google). Arcus’ therapies target small molecules, aimed at helping shrink tumors.

  • After a spike of more than 50% after the news story broke, Arcus has a market value of $ 716.3 Million, Alphabet owns c. 11%
  • Gilead continues to expand through acquisitions into pharmaceutical Research focused on cancer treatments harnessing the immune system to fight tumors.
    • Gilead acquired Forty Seven (in which Alphabet also held a stake) in a $4.9 billion deal last month, and
    • In 2017 Gilead acquired Kite Pharma for $11 Billion. The investment has so far yet to pay off
  • Development partnerships between Gilead and Arcus might as well be possible

Update: Market participants seem to take the news negatively as GILD is trading lower today with -4% vs S&P trading lower with -2% only


One thought on “News📰: Gilead to Buy Arcus Stake

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s